Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926867 | 0.84 | RAB9A (0.47) | TSHRKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29847389 | 0.83 | ALDH1A1 (0.49) | TSHRALDH1A1GLASMN1; SMN2HPGD | |
| SCHEMBL2338368 | 0.83 | ALDH1A1 (0.49) | TSHRALDH1A1GLASMN1; SMN2HPGD | |
| SCHEMBL7962015 | 0.83 | ALDH1A1 (0.49) | TSHRALDH1A1GLASMN1; SMN2HPGD | |
| SCHEMBL7962011 | 0.83 | ALDH1A1 (0.49) | TSHRALDH1A1GLASMN1; SMN2HPGD | |
| SCHEMBL30524198 | 0.83 | ALDH1A1 (0.49) | TSHRKMT2AMEN1ALDH1A1GLA | |
| SCHEMBL4892470 | 0.83 | ALDH1A1 (0.49) | TSHRKMT2AMEN1ALDH1A1GLA | |
| SCHEMBL9803136 | 0.82 | ALDH1A1 (0.59) | TSHRKMT2AMEN1ALDH1A1GLA | |
| SCHEMBL4363233 | 0.81 | ALDH1A1 (0.46) | TSHRKMT2AMEN1ALDH1A1GLA | |
| SCHEMBL21296293 | 0.81 | ALDH1A1 (0.50) | TSHRKMT2AMEN1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2015042414-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME | Karyopharm Therapeutics Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015042414-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME | Karyopharm Therapeutics Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | PAK4, PAK5, PAK1 | TSHR 4639/4885KMT2A 980/4885MEN1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.